NEW YORK (GenomeWeb) – MolecularMD has received accreditation from the College of American Pathologists for its next-generation sequencing laboratory in Cambridge, Mass.
The accreditation follows CLIA certification of the lab earlier this year. Molecular MD opened the lab in 2012 to complement its RT-PCR and immunohistochemistry laboratory in Portland, Ore.
The company has developed NGS cancer panels on multiple platforms, specializing in tissue- and blood-based assays for retrospective evaluations and prospective clinical trial enrollment.
The NGS laboratory has validated methods and platforms for circulating tumor DNA analysis. It recently validated the Thermo Fisher Ion AmpliSeq Cancer Hotspot Panel v2 for the detection of somatic hotspot mutations with less than 1 percent allele frequency in ctDNA.
The company has also adopted Thermo Fisher's Oncomine Cancer Research panel for the analysis of mutations, copy number alterations, and fusions in cancer genomes.